References
- Kumar A, Abbas W, Herbein G. HIV-1 latency in monocytes/macrophages. Viruses. 2014;6:1837-60. https://doi.org/https://doi.org/10.3390/v6041837 PMID:24759213
- Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology [Internet]. 2009;6:51. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2697150&tool=pmcentrez&rendertype=abstract https://doi.org/https://doi.org/10.1186/1742-4690-6-51
- Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel M-R, Ghattas G, Brenchley JM, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893-900. https://doi.org/https://doi.org/10.1038/nm.1972 PMID:19543283
- Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-7. https://doi.org/https://doi.org/10.1038/8394 PMID:10229227
- Kyei GB, Dinkins C, Davis AS, Roberts E, Singh SB, Dong C, Wu L, Kominami E, Ueno T, Yamamoto A, et al. Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. J Cell Biol. 2009;186:255-68. https://doi.org/https://doi.org/10.1083/jcb.200903070 PMID:19635843
- Stevenson M. HIV-1 pathogenesis. Nat Med. 2003;9:853-60. https://doi.org/https://doi.org/10.1038/nm0703-853 PMID:12835705
- Chun T-W, Davey RT, Engel D, Lane HC, Fauci AS. AIDS: Re-emergence of HIV after stopping therapy. Nature [Internet]. 1999;401:874-5. Available from: https://doi.org/https://doi.org/10.1038/44755
- Ren X-X, Ma L, Sun W-W, Kuang W-D, Li T-S, Jin X, Wang J-H. Dendritic cells maturated by co-culturing with HIV-1 latently infected Jurkat T cells or stimulating with AIDS-associated pathogens secrete TNF-alpha to reactivate HIV-1 from latency. Virulence 2017. https://doi.org/https://doi.org/10.1080/21505594.2017.1356535
- Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, et al. An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. PLoS Pathog. 2013;9:1-15. https://doi.org/https://doi.org/10.1371/journal.ppat.1003834
- Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Discov [Internet]. 2012;11:937-57. Available from: https://doi.org/https://doi.org/10.1038/nrd3871
- Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A [Internet]. 1989;86:2336-40. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=286907&tool=pmcentrez&rendertype=abstract https://doi.org/https://doi.org/10.1073/pnas.86.7.2336
- Gardner KE, Allis CD, Strahl BD. Operating on chromatin, a colorful language where context matters. J Mol Biol [Internet]. 2011;409:36-46. Available from: https://doi.org/https://doi.org/10.1016/j.jmb.2011.01.040
- Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med [Internet]. 2014;20:425-9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3981911&tool=pmcentrez&rendertype=abstract%5Cnhttp://www.nature.com/doifinder/https://doi.org/10.1038/nm.3489 https://doi.org/https://doi.org/10.1038/nm.3489
- Smith-Garvin JE, Koretzky 1 Gary A, Jordan MS, Koretzky G. T Cell Activation. Annu Rev Immunol. 2009;27:591-619. https://doi.org/https://doi.org/10.1146/annurev.immunol.021908.132706 PMID:19132916
- Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, et al. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLOS Pathog [Internet]. 2015;11:e1005063. Available from: https://doi.org/https://doi.org/10.1371/journal.ppat.1005063
- Laird GM, Bullen CK, Rosenbloom DIS, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. Ex vivo analysis identifies effective HIV-1 latency – reversing drug combinations. The journal of clinical investigation. 2015;125:1-12.
- Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med [Internet]. 2016;22:1043-1049. doi:https://doi.org/10.1038/nm.4156. Available from: http://www.nature.com/doifinder/https://doi.org/10.1038/nm.4156
- Hosmane NN, Kwon KJ, Bruner KM, Capoferri AA, Beg S, Rosenbloom DIS, Keele BF, Ho Y-C, Siliciano JD, Siliciano RF. Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. J Exp Med. 2017;214:959 LP–972. https://doi.org/https://doi.org/10.1084/jem.20170193
- Ho Y-C, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DIS, Lai J, Blankson JN, Siliciano JD, Siliciano RF. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure. Cell [Internet]. 2013;155:540-51. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0092867413011574 https://doi.org/https://doi.org/10.1016/j.cell.2013.09.020
- Pasternak AO, De Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, Lukashov VV. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis. 2012;206:1443-52. https://doi.org/https://doi.org/10.1093/infdis/jis502 PMID:22927449
- Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Böni J, Hirschel B, Weber R, Trkola A, Günthard HF, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008;105:16725-30. https://doi.org/https://doi.org/10.1073/pnas.0804192105
- Wong JK, Hezareh M, Günthard HF, Havlir D V, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-5. https://doi.org/https://doi.org/10.1126/science.278.5341.1291 PMID:9360926
- van der Sluis RM, van Capel TMM, Speijer D, Sanders RW, Berkhout B, de Jong EC, Jeeninga RE, van Montfort T. Dendritic cell type-specific HIV-1 activation in effector T cells. Aids. 2015;29:1003-14. https://doi.org/https://doi.org/10.1097/QAD.0000000000000637
- van der Sluis RM, van Montfort T, Pollakis G, Sanders RW, Speijer D, Berkhout B, Jeeninga RE. Dendritic Cell-induced Activation of Latent HIV-1 Provirus in Actively Proliferating Primary T Lymphocytes. PLoS Pathog. 2013;9(3). https://doi.org/https://doi.org/10.1371/journal.ppat.1003259
- Marini A, Harper JM, Romerio F. An In Vitro System to Model the Establishment and Reactivation of HIV-1 Latency. J Immunol. 2008;181:7713-20. https://doi.org/https://doi.org/10.4049/jimmunol.181.11.7713
- Chun BT, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 Replication in Latently Infected CD4+ T Cells Using a Combination of Cytokines. J Exp Med. 1998;188:83-91. https://doi.org/https://doi.org/10.1084/jem.188.1.83 PMID:9653086
- Meier A, Bagchi A, Sidhu HK, Alter G, Suscovich TJ, Kavanagh DG, Streeck H, Brockman MA, LeGall S, Hellman J, et al. Up-regulation of PD-L1 on Monocytes and Dendritic Cells by HIV-1 derived TLR Ligands. AIDS. 2008;22:655-8. https://doi.org/https://doi.org/10.1097/QAD.0b013e3282f4de23
- Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, ten Berge IJ, Yong SL, Fox CH, Roos MT, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS. 1999;13:2405-10. https://doi.org/https://doi.org/10.1097/00002030-199912030-00012 PMID:10597782
- Delagrèverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ. Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents. Open Forum Infect Dis. 2016;3. https://doi.org/https://doi.org/10.1093/ofid/ofw189